Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Tandem Diabetes Care Is Dropping Today

By Brian Feroldi - Updated Apr 10, 2019 at 8:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares tumble on a slow news day. What can explain the double-digit move?

What happened

Shares of Tandem Diabetes Care (TNDM 4.43%), a medical device company focused on diabetes, fell about 10% as of 2:15 p.m. EST on Wednesday. The decline is most likely attributable to negative sentiment from Wall Street related to a few of the company's peers.

So what

Here's an overview of some of the news that is impacting diabetes-focused medical device companies today:

  • An analyst at Morgan Stanley lowered their price target on Insulet (PODD 3.91%) -- which competes directly with Tandem -- from $105 to $90 in a research report issued on Wednesday. Insulet's stock is down about 8% today in response.  
  • Morgan Stanley also lowered its price target on DexCom (DXCM 4.16%) -- a diabetes company focused on continuous glucose monitoring that works with Tandem -- to $135 from $150. Dexcom's stock is down about 4% in resopnse.
  • An analyst at Citigroup lowered their rating on Medtronic (MDT 1.82%) -- which makes both insulin pumps and continuous glucose monitors -- to neutral from buy, and the price target was lowered to $96 from $109. Shares are falling about 3% in response.
  • A paper was published in the journal Cell Metabolism stating that researchers have found that a new cocktail of drugs can help the body to reactivate insulin-producing cells. While it is still very early, this research could be an important step in curing diabetes. 

Add it all up, and it isn't surprising to see that Tandem's stock is getting whacked today, too.

Man with head against wall in conference room

Image source: Getty Images.

Now what

2018 was a remarkable year for Tandem, so it is possible that its shares are taking a step back today thanks to profit-taking now that investors won't be on the hook for capital gains tax until 2020. 

Regardless of the reason for today's drop, I see nothing that suggests the company is any different today than it was at the end of 2018. If you were bullish on Tandem just a few days ago, then there doesn't seem to be a reason to change your tune today.

Check out the latest Tandem Diabetes Care earnings call transcript.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tandem Diabetes Care Stock Quote
Tandem Diabetes Care
$61.81 (4.43%) $2.62
Medtronic plc Stock Quote
Medtronic plc
$91.38 (1.82%) $1.63
DexCom, Inc. Stock Quote
DexCom, Inc.
$77.63 (4.16%) $3.10
Insulet Corporation Stock Quote
Insulet Corporation
$226.46 (3.91%) $8.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.